If you are looking for a connection between prostate cancer treatment and sterility then you have come to the right place, but first you need to be patient and understand what you are dealing with. Prostate cancer is the malignant tumor that touches the prostate, especially in the shape of an adeno-carcinoma. Prostate cancer is extremely frequent, affecting one in two men aged over 60.



Most often, this type of cancer does not show ay type of symptoms. In other cases, it is translated through blood in the urine and through an abnormal increase in the number of urination, which becomes difficult, since the patient needs to force the evacuation of the bladder. Finally, prostate cancer can, when metastasized, cause fatigue, anemia, loss of weight, and so on.



Prostate cancer is a malignant tumor with a very slow evolution, which does not constitute the main cause for death in the older patients carrying this affliction. A combination of biomarkers detectable solely in urine can now lead to the easier identification of prostate cancer. Thus, the classic blood tests could be dropped when seeking clues of prostate cancer. American researchers from the University of Michigan have discovered that a simple urine test meant to identify the presence of four proteins had an 80% precision rate in the identification of prostate cancer.

Prostate cancer treatment and sterility

- The choice of each therapeutic method depends on the age and general state of the patient, as well as the evolution of the illness, namely if it is local or metastasized. When the cancer is local, in the prostate alone, the treatment involves total ablation of the prostate, of the seminal vesicles and of the differential ampoules, prostatic radiotherapy or, perhaps, chemotherapy. These methods allow complete curing of the cancer in a very high number of cases. These treatments, however, are only proposed to patients below 70. When the cancer has metastasized or when the patient is very aged and has a poor general state, aggressive cures are not the case: hormone therapy allows a remission that often lasts several years.

- The surgical method consist of applying an partial endoscopic ablation of the prostate, when the tumor blocks off the prostatic urethra, or of surgically removing the entire prostate, the seminal vesicles and the differential ampoules (total or radical prostatectomy).

- External radiotherapy of the prostate and of the pelvic ganglions envisions curing the cancer by destroying the entire tumor and its extensions. This treatment can result in urinary incontinence, impotence and/or irritation of the bladder and rectum.

- Hormone therapy is reserved for prostate cancers that have metastasized. This is a palliative treatment that consists of suppressing the secretion of androgen hormones by the testicles. These hormones stimulate the growth of the cancer. The therapy is based on two methods:



- pulpectomy (surgical ablation of the functional tissue in the testicles) entails sterility and impotence

- medical treatment also envisions the suppression of androgenic testicular secretion. Administered in a continuous manner, the gonadoliberin agonists and the anti-androgens, which act on the pituitary gland and on the prostate, are equally efficient as a pulpectomy, but they too entail sterility and impotence.

- chemotherapy is rarely used because of its low success rate against prostate cancer.